Dr Reddy’s semaglutide supply delay hits stock in 2026

Supply delay disclosed as API issue emerges

Dr Reddy’s Laboratories said on Thursday, July 9, 2026, that it is delaying commercial supplies of semaglutide due to an issue linked to the active pharmaceutical ingredient used in the drug. The disclosure came as the company positioned semaglutide as an important product in its metabolic therapy plans, including diabetes care. The company did not share a revised timeline for when supplies would normalise. It also did not provide further technical details beyond the nature of the quality finding. The announcement had an immediate impact on investor sentiment because semaglutide is widely tracked as a key growth opportunity. The delay also comes amid a broader focus on supply continuity for complex products.

What Dr Reddy’s said about the quality finding

In its statement, Dr Reddy’s said certain batches of semaglutide were found to be out of specification. The company attributed the delay to an issue related to the active pharmaceutical ingredient (API) used in the product. It said it is investigating the root cause and taking measures to ensure product quality. Dr Reddy’s did not specify which markets are affected by the delay, beyond stating that commercial supplies would be postponed for a certain period. The company’s messaging focused on quality assurance steps rather than commercial targets. It also avoided providing a quantified impact on volumes or revenue.

Patient safety and regulatory filings flagged as unaffected

Dr Reddy’s said there is no impact on patient safety. It also said there is no impact on the product’s existing global regulatory filings. This distinction matters because semaglutide products operate under close regulatory scrutiny, and any quality-related development can raise questions around compliance and approvals. The company’s statement framed the issue as a specification deviation in certain batches and not a safety event. Still, the lack of clarity on duration means investors will likely watch for follow-up disclosures. Any resumption schedule, or clarity on the scope of impacted inventory, could influence near-term expectations.

Stock reaction: shares fall over 5% on BSE

The market reacted sharply to the update. At around 12:30 p.m., Dr Reddy’s shares were down 5.24%, trading at ₹1,278 per share on the BSE. The decline reflected concerns about execution risk in a product category where supply reliability is critical. It also highlighted the sensitivity of the stock to developments in the company’s semaglutide programme. The move came even as the company stated that patient safety and regulatory filings were unaffected. For investors, the immediate question is less about filings and more about how quickly the company can restore commercial supplies.

Semaglutide plans: India launch and Canada strategy in focus

Separate updates around semaglutide have kept attention high on Dr Reddy’s progress in this market. The company has launched semaglutide in India and secured approval in Canada, according to an ET Intelligence Group note cited in the provided material. Another Reuters report dated May 12 said the company was preparing to introduce a generic version of Ozempic in Canada within the coming days. The company has also pointed to broader expansion plans across markets such as Brazil after patent expirations. In India, Dr Reddy’s rolled out its injectable semaglutide drug, Obeda, in March to manage diabetes, as stated in the provided text.

Patent expiry and competitive backdrop in India

The semaglutide opportunity in India has been shaped by patent expiry timing. The provided material notes that the patent for semaglutide in India lapsed in March, and also states in a February 25 Reuters report that the patent will lapse in India in March 2026. Regardless of the phrasing, the context presented is that India’s market opened up quickly for generic competition, raising the stakes for day-one readiness. Dr Reddy’s has stated it would aim for a day-one launch in India. The company has also been described as the first Indian company to receive Drugs Controller General of India (DCGI) approval for generic semaglutide. With multiple companies expected to pursue the segment, supply continuity becomes a differentiator alongside pricing and physician confidence.

Targets and pricing signals cited in earlier reporting

A February 25 Reuters report cited G.V. Prasad, Co-Chairman and Managing Director, saying Dr Reddy’s aims to distribute approximately 12 million injectable semaglutide within its first year of sales. The same report said the company planned a competitive price that could be up to 60% lower than the branded counterpart. Dr Reddy’s, however, has also declined to provide revenue projections, according to the provided material. That makes operational execution and quality control the main measurable indicators in the near term. Any supply disruption, even if temporary, can complicate early momentum in a high-demand category.

Financial context: FY26 profit pressure and US headwinds

The semaglutide update lands at a time when Dr Reddy’s broader performance has been under pressure in key markets. An ET Intelligence Group note cited in the provided text said the company reported a 26% fall in net profit in FY26, weighed down by pressure on its US business. It added that excluding disruptions, operations continued to grow at a healthy pace in India, Europe and emerging markets. The note also said margins are expected to improve in FY27, supported by better product mix, cost controls and the absence of major one-off expenses. In the US, revenue was described as falling sharply due to the loss of exclusivity for Revlimid. The same note said the company expects its base generics business, excluding Revlimid, to return to double-digit growth in FY27, supported by 27 new launches and a shift toward higher-value products.

Market impact: what investors will track next

The July 9 disclosure increases focus on three near-term variables: the root-cause outcome, the timeline for resuming commercial supplies, and whether the issue has any knock-on effects on planned market expansions. Dr Reddy’s has said it is taking measures to ensure product quality, but it has not given a time-bound update. For investors, clarity on when supplies restart is important because semaglutide has been repeatedly positioned as a potential growth driver, particularly after India’s market opened up and with Canada approvals in place. The stock reaction suggests the market is pricing in uncertainty rather than confirmed long-term damage. Any future update that quantifies impacted batches, production status, or expected supply recovery would likely be closely watched.

Key facts at a glance

Conclusion

Dr Reddy’s delay in commercial semaglutide supplies, triggered by out-of-specification batches linked to the API, has added short-term uncertainty to a product that the company and investors have been treating as strategically important. The company’s assurance that patient safety and existing regulatory filings are unaffected addresses a key risk area, but it has not given a timeline for normalisation. Markets will now look for follow-up disclosures on the scope of the issue, the corrective actions taken, and the expected timing of supply resumption. The next updates will be important in the context of Dr Reddy’s broader efforts to strengthen growth after FY26 profit pressure and ongoing shifts in its US generics mix.